ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Offsetting Assets [Line Items]
Accumulated deficit	$ 154,566,728	$ 142,358,554
Net loss	(12,208,174)	(12,029,786)
Cash and cash equivalents	9,100,000
Cash balances over insured amount	568,000
Cash equivalents of US treasury bills	4,700,000
Restricted cash	87,506	87,506
Uncertain tax positions	0	0
Asset impairment charges	$ 0	$ 0
Antidilutive shares	124,028	204,501
Deferred offering costs	$ 278,000
Revenue recognized from contract	0	$ 574,245
Research and development expenses	$ 2,520,000	2,745,000
Melanoma Cancer Contract [Member]
Offsetting Assets [Line Items]
Revenue recognized from contract		$ 574,245